CFO share grant at Park Ha Biological Technology (BYAH) after split

Rhea-AI Filing Summary

Zhu Xiaoyan reported acquisition or exercise transactions in this Form 4 filing.

Park Ha Biological Technology Co., Ltd. reported that CFO Zhu Xiaoyan received a grant of 112,500 Class A Ordinary Shares on August 3, 2026 at $0.18 per share, purchased from the company under its 2026 Share Incentive Plan. Following this award, she directly holds 112,500 shares. The reported share amounts reflect a 1-for-8 reverse stock split effective August 6, 2026.

Insider Trade Summary

Net Buyer: 112,500 shares

Net Buy 1 txn

Insider Zhu Xiaoyan

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares F2, F1	112,500	$0.18	$20K

Holdings After Transaction: Class A Ordinary Shares — 112,500 shares (Direct)

Footnotes (2)

1. F1. Purchase of Class A ordinary shares from Park Ha Biological Technology Co., Ltd. pursuant to its 2026 Share Incentive Plan.
2. F2. On August 6, 2026, Park Ha Biological Technology Co., Ltd. effected a 1-for-8 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Key Figures

Shares granted: 112,500 shares Grant price: $0.18 per share Shares owned after grant: 112,500 shares +1 more

4 metrics

Shares granted 112,500 shares Class A Ordinary Shares granted to CFO on August 3, 2026

Grant price $0.18 per share Purchase price under 2026 Share Incentive Plan

Shares owned after grant 112,500 shares Direct holdings of CFO following the reported transaction

Reverse stock split ratio 1-for-8 Reverse stock split effective August 6, 2026; figures adjusted accordingly

Key Terms

Class A Ordinary Shares, 2026 Share Incentive Plan, Reverse Stock Split

3 terms

Class A Ordinary Shares financial

"Security title reported as Class A Ordinary Shares for the transaction."

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

2026 Share Incentive Plan financial

"Purchase of Class A ordinary shares pursuant to its 2026 Share Incentive Plan."

Reverse Stock Split financial

"Effected a 1-for-8 reverse stock split (the Reverse Stock Split)."

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 08:58 AM Accepted by SEC EDGAR 08/07/2026 - 08:58 AM Learn about SEC filing dates

FAQ

What insider transaction did BYAH's CFO report?

CFO Zhu Xiaoyan reported acquiring 112,500 Class A Ordinary Shares of Park Ha Biological on August 3, 2026. The shares were purchased from the company at $0.18 per share under its 2026 Share Incentive Plan, with amounts adjusted for a 1-for-8 reverse stock split.

How many BYAH shares did CFO Zhu Xiaoyan acquire and at what price?

Zhu Xiaoyan acquired 112,500 Class A Ordinary Shares of BYAH at $0.18 per share. The acquisition was recorded as a grant or award purchase from Park Ha Biological under its 2026 Share Incentive Plan, with the share count reflecting a 1-for-8 reverse stock split.

What is Park Ha Biological (BYAH)'s 2026 Share Incentive Plan mentioned in the filing?

The 2026 Share Incentive Plan is the program through which CFO Zhu Xiaoyan purchased 112,500 Class A Ordinary Shares from Park Ha Biological. The filing describes the transaction as a purchase from the company pursuant to this plan, serving as part of her equity-based compensation.

How did the reverse stock split affect the reported BYAH share amounts?

Park Ha Biological effected a 1-for-8 reverse stock split on August 6, 2026, and the reported Form 4 figures reflect this adjustment. The 112,500 shares shown for CFO Zhu Xiaoyan are already post-split amounts, aligning the grant data with the new share structure.

What is Zhu Xiaoyan's BYAH shareholding after the reported grant?

After the August 3, 2026 transaction, CFO Zhu Xiaoyan directly holds 112,500 Class A Ordinary Shares of BYAH. This post-transaction balance matches the number of shares acquired in the grant and already incorporates the company's 1-for-8 reverse stock split adjustment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zhu Xiaoyan

(Last) (First) (Middle)

6-201 ZIJINMEN GARDEN, LIANGXI DISTRICT

(Street)

WUXI 214000

(City) (State) (Zip)

CHINA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Park Ha Biological Technology Co., Ltd. [ BYAH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	08/03/2026		A		112,500(2)	A	$0.18(1)	112,500(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Purchase of Class A ordinary shares from Park Ha Biological Technology Co., Ltd. pursuant to its 2026 Share Incentive Plan.

2. On August 6, 2026, Park Ha Biological Technology Co., Ltd. effected a 1-for-8 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

	/s/ Zhu Xiaoyan	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)